Natco Pharma Ltd receives U.S. FDA EIR for its Parawada unit, with the inspection classified VAI after four Form 483 observations.
- Inspection covered the finished dosage formulations unit in Parawada, Visakhapatnam.
- The U.S. FDA conducted the inspection from 17–21 August 2026.
